Table 3.

Multiple Linear Regression to Identify Predictors of IOC at Follow-Up

Variable	Negative Impact Summary						Positive Impact Summary
	Adjusted for Initial IOC Negative Impact			Adjusted for Initial IOC Negative Impact and Other Predictors (n = 549)			Adjusted for Initial IOC Positive Impact			Adjusted for Initial IOC Positive Impact and Other Predictors (n = 546)
	Coefficient, β	SE	P	Coefficient, β	SE	P	Coefficient, β	SE	P	Coefficient, β	SE	P
Initial IOC Negative or Positive Impact	0.78	0.03	< .001	0.62	0.04	< .001	0.73	0.03	< .001	0.72	0.03	< .001
Demographicsa
Female sex	−0.02	0.04	.729				0.10	0.05	.037	0.12	0.05	.010
Nonwhite race	−0.06	0.07	.344				0.006	0.07	.929
Income < $30,000	0.10	0.06	.072	0.07	0.06	.197	−0.01	0.06	.850
Less than college degree	−0.02	0.05	.726				−0.01	0.05	.762
Not married	−0.02	0.06	.755				0.09	0.06	.118
Age at study enrollment	−0.003	0.002	.056	−0.003	0.002	.074	−0.004	0.002	.041	−0.004	0.002	.036
Clinical characteristicsb
Years since diagnosis	0.001	0.003	.792				−0.002	0.003	.595
Recurrence in last 5 yearsc	0.04	0.05	.423				0.05	0.05	.340
Systemic treatment statusd
Received chemotherapy	0.11	0.07	.094	0.13	0.07	.056	0.06	0.07	.412	0.05	0.07	.499
Received biologic treatment	0.12	0.12	.310	0.18	0.12	.126	0.11	0.12	.361	0.12	0.12	.304
Chemotherapy-biologic therapy interaction	0.14	0.08	.073	0.15	0.08	.058	0.14	0.08	.083	0.13	0.08	.109
Ever had transplantation	0.26	0.08	.002	0.26	0.08	.001	0.16	0.09	.061	0.12	0.09	.180
No systemic treatment ever	−
Comorbidity scoree	0.003	0.005	.511				0.003	0.005	.606
Lymphoma symptom scoref	−0.15	0.04	< .001	−0.14	0.04	< .001	−0.03	0.03	.341
Psychosocial statusg
Social Supporth	−0.003	0.001	.020	−0.003	0.001	.024	−0.0005	0.001	.734	0.001	0.002	.451
Δ Social Support	−0.001	0.002	.652				0.004	0.002	.008	0.004	0.002	.008
Model-adjusted R2 P			.50			.54			.52			.55

Abbreviation: IOC, Impact of Cancer.

^aDemographic variables are from the 2005 survey.

^bClinical variables are from the 2005 survey (years since diagnosis, comorbidity, lymphoma symptom score, and systemic treatment status) and the follow-up 2010 survey (systemic treatment status and recurrence in last 5 years).

^cParticipants who reported having a recurrence of their lymphoma within the last 5 years or who have never been in remission.

^dMutually exclusive categories; participants reported receiving systemic treatment (ie, chemotherapy, biologic therapy such as rituximab, transplantation) at initial and/or follow-up survey.

^eSelf-Administered Comorbidity Questionnaire; possible score range, 0 to 42.

^fFunctional Assessment of Cancer Therapy–Lymphoma module; 15 items, possible score range, 0 to 60. Lower scores indicate greater symptoms.

^gPsychosocial variables are from the 2005 survey except for change variables.

^hMedical Outcomes Study Social Support total score; possible score range, 0 to 100; higher scores indicate higher support.